Pacira BioSciences Appoints Samit Hirawat to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21h ago
0mins
Pacira BioSciences (PCRX) announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members. Most recently, Dr. Hirawat served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb (BMY).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PCRX
Wall Street analysts forecast PCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCRX is 29.71 USD with a low forecast of 23.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 19.850
Low
23.00
Averages
29.71
High
38.00
Current: 19.850
Low
23.00
Averages
29.71
High
38.00
About PCRX
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
San Francisco Expands Free Childcare Access, Saving Families Thousands Annually
- Income Support for Families: San Francisco's plan provides free childcare for children under five to families earning less than $230,000, while those earning up to $310,000 qualify for partial subsidies, potentially saving families tens of thousands of dollars annually.
- Addressing Living Costs: The initiative targets childcare costs that can reach $30,000 annually for full-time infant care, with city officials stating that this move offers meaningful economic relief for middle-class families, helping them remain in the city.
- Funding Assurance: Funding for the initiative will come from a commercial rent tax approved by voters in 2018, with estimates suggesting that unused revenue will support approximately 20,000 children through 2032, ensuring the program's sustainability.
- Political Context: Mayor Daniel Lurie, as part of a growing group of Democratic leaders, is pushing this affordability agenda, reflecting a broader focus on the economic pressures facing middle-class families post-2024 election cycle, with similar efforts underway in New York.
Continue Reading
Pacira BioSciences Partners with LG Chem to Expand Access to EXPAREL in Asia-Pacific Markets
- Market Expansion Partnership: Pacira BioSciences has entered into an agreement with LG Chem, granting exclusive rights to commercialize EXPAREL in Asia-Pacific markets, aiming to enhance patient access to opioid-sparing postsurgical pain management, aligning with global trends to reduce opioid dependency.
- Financial Benefit Structure: Under the terms of the deal, Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future commercial sales by LG Chem, providing a stable revenue stream and enhancing financial flexibility for Pacira.
- Market Authorization Plans: LG Chem intends to file for marketing authorizations for EXPAREL in South Korea and Thailand within the next six months, a move that will not only expedite product availability but also strengthen Pacira's market position in the Asia-Pacific region.
- Stock Market Reaction: Following the announcement, Pacira's stock price rose by 0.87% to $23.13 in pre-market trading on Nasdaq, reflecting positive market sentiment towards the partnership and potentially driving future growth prospects for the company.
Continue Reading